berberine has been researched along with Chronic Disease in 15 studies
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Berberine (BBR) is a multi-target drug (MTD) that has proven effective in the treatment of metabolism-related chronic diseases (CDs)." | 9.05 | Berberine in the treatment of metabolism-related chronic diseases: A drug cloud (dCloud) effect to target multifactorial disorders. ( Foiani, M; Jiang, JD; Kong, WJ; Vernieri, C, 2020) |
| "Berberine, initially isolated from Rhizoma Coptidis (Huanglian in Chinese), is a drug used to treat gastrointestinal disorders such as colitis." | 7.96 | Circadian pharmacological effects of berberine on chronic colitis in mice: Role of the clock component Rev-erbα. ( Gao, L; Lin, Y; Wang, S; Wu, B; Yang, Z; Zhou, Z, 2020) |
| " Although berberine, an isoquinoline alkaloid, has been revealed to exert protective effects on experimental colitis, the underlying molecular mechanism in chronic intestinal inflammation remains ill-defined." | 7.96 | Intervention of oncostatin M-driven mucosal inflammation by berberine exerts therapeutic property in chronic ulcerative colitis. ( Fan, C; Feng, C; He, P; Li, H; Lu, H; Lu, Q; Tang, W; Xiang, C; Yang, X; Yang, Y; Zhang, Z; Zhu, F; Zuo, J, 2020) |
| "Berberine has been established as a potential drug for inflammation and metabolic disorder." | 7.96 | Berberine ameliorates obesity-induced chronic inflammation through suppression of ER stress and promotion of macrophage M2 polarization at least partly via downregulating lncRNA Gomafu. ( Fan, DH; Han, YB; Li, WZ; Liu, L; Tian, M; Wang, XX; Wu, F, 2020) |
| "It has been reported that berberine is valuable for long-term treatment of ventricular premature beats (VPBs) and leads to a decrease in mortality for patients with congestive heart failure (CHF)." | 7.70 | Relationship between the clinical effects of berberine on severe congestive heart failure and its concentration in plasma studied by HPLC. ( Zeng, X, 1999) |
| "Berberine (BBR) is an isoquinoline alkaloid derived from various medicinal herbs." | 5.48 | Berberine demonstrates anti-inflammatory properties in Helicobacter pylori-infected mice with chronic gastritis by attenuating the Th17 response triggered by the B cell-activating factor. ( Dang, Z; Jia, Y; Li, X; Wu, X, 2018) |
| "Berberine was orally administrated in normal or CUMS mice for successive four weeks." | 5.46 | Berberine attenuates depressive-like behaviors by suppressing neuro-inflammation in stressed mice. ( Bai, L; Fang, XY; Li, YC; Liu, YM; Niu, L; Wang, LL; Yi, LT, 2017) |
| "Colitis was induced by two cycles of 2." | 5.43 | Berberine ameliorates chronic relapsing dextran sulfate sodium-induced colitis in C57BL/6 mice by suppressing Th17 responses. ( Bian, ZX; Fatima, S; Hu, DD; Lee, NP; Li, YH; Lin, CY; Mu, HX; Xiao, HT, 2016) |
| "Berberine (BBR) is a multi-target drug (MTD) that has proven effective in the treatment of metabolism-related chronic diseases (CDs)." | 5.05 | Berberine in the treatment of metabolism-related chronic diseases: A drug cloud (dCloud) effect to target multifactorial disorders. ( Foiani, M; Jiang, JD; Kong, WJ; Vernieri, C, 2020) |
| "Berberine, initially isolated from Rhizoma Coptidis (Huanglian in Chinese), is a drug used to treat gastrointestinal disorders such as colitis." | 3.96 | Circadian pharmacological effects of berberine on chronic colitis in mice: Role of the clock component Rev-erbα. ( Gao, L; Lin, Y; Wang, S; Wu, B; Yang, Z; Zhou, Z, 2020) |
| " Although berberine, an isoquinoline alkaloid, has been revealed to exert protective effects on experimental colitis, the underlying molecular mechanism in chronic intestinal inflammation remains ill-defined." | 3.96 | Intervention of oncostatin M-driven mucosal inflammation by berberine exerts therapeutic property in chronic ulcerative colitis. ( Fan, C; Feng, C; He, P; Li, H; Lu, H; Lu, Q; Tang, W; Xiang, C; Yang, X; Yang, Y; Zhang, Z; Zhu, F; Zuo, J, 2020) |
| "Berberine has been established as a potential drug for inflammation and metabolic disorder." | 3.96 | Berberine ameliorates obesity-induced chronic inflammation through suppression of ER stress and promotion of macrophage M2 polarization at least partly via downregulating lncRNA Gomafu. ( Fan, DH; Han, YB; Li, WZ; Liu, L; Tian, M; Wang, XX; Wu, F, 2020) |
| "It has been reported that berberine is valuable for long-term treatment of ventricular premature beats (VPBs) and leads to a decrease in mortality for patients with congestive heart failure (CHF)." | 3.70 | Relationship between the clinical effects of berberine on severe congestive heart failure and its concentration in plasma studied by HPLC. ( Zeng, X, 1999) |
| " There were, however, very few clinical reports of adverse reaction attributable to RC or CP in oral TCM concoction." | 2.77 | Berberine-induced haemolysis revisited: safety of Rhizoma coptidis and Cortex phellodendri in chronic haematological diseases. ( Lim, LC; Linn, YC; Lu, J; Ng, HS; Sun, H; Sun, J; Zhou, Y, 2012) |
| "Berberine (BBR) is an isoquinoline alkaloid derived from various medicinal herbs." | 1.48 | Berberine demonstrates anti-inflammatory properties in Helicobacter pylori-infected mice with chronic gastritis by attenuating the Th17 response triggered by the B cell-activating factor. ( Dang, Z; Jia, Y; Li, X; Wu, X, 2018) |
| "Berberine was orally administrated in normal or CUMS mice for successive four weeks." | 1.46 | Berberine attenuates depressive-like behaviors by suppressing neuro-inflammation in stressed mice. ( Bai, L; Fang, XY; Li, YC; Liu, YM; Niu, L; Wang, LL; Yi, LT, 2017) |
| "Colitis was induced by two cycles of 2." | 1.43 | Berberine ameliorates chronic relapsing dextran sulfate sodium-induced colitis in C57BL/6 mice by suppressing Th17 responses. ( Bian, ZX; Fatima, S; Hu, DD; Lee, NP; Li, YH; Lin, CY; Mu, HX; Xiao, HT, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 6 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takahara, M | 1 |
| Takaki, A | 1 |
| Hiraoka, S | 1 |
| Adachi, T | 1 |
| Shimomura, Y | 1 |
| Matsushita, H | 1 |
| Nguyen, TTT | 1 |
| Koike, K | 1 |
| Ikeda, A | 1 |
| Takashima, S | 1 |
| Yamasaki, Y | 1 |
| Inokuchi, T | 1 |
| Kinugasa, H | 1 |
| Sugihara, Y | 1 |
| Harada, K | 1 |
| Eikawa, S | 1 |
| Morita, H | 1 |
| Udono, H | 1 |
| Okada, H | 1 |
| Zhou, Z | 1 |
| Lin, Y | 1 |
| Gao, L | 1 |
| Yang, Z | 1 |
| Wang, S | 1 |
| Wu, B | 1 |
| Tew, XN | 1 |
| Xin Lau, NJ | 1 |
| Chellappan, DK | 1 |
| Madheswaran, T | 1 |
| Zeeshan, F | 1 |
| Tambuwala, MM | 1 |
| Aljabali, AA | 1 |
| Balusamy, SR | 1 |
| Perumalsamy, H | 1 |
| Gupta, G | 1 |
| Oliver, BG | 1 |
| Hsu, A | 1 |
| Wark, P | 1 |
| Reddy, K | 1 |
| Wadhwa, R | 1 |
| Hansbro, PM | 1 |
| Dua, K | 1 |
| Kong, WJ | 1 |
| Vernieri, C | 1 |
| Foiani, M | 1 |
| Jiang, JD | 1 |
| Yang, T | 1 |
| Wang, R | 1 |
| Zhang, J | 2 |
| Bao, C | 1 |
| Li, R | 1 |
| Chen, X | 1 |
| Wu, S | 1 |
| Wen, J | 1 |
| Wei, S | 1 |
| Li, H | 2 |
| Cai, H | 1 |
| Yang, X | 2 |
| Zhao, Y | 1 |
| Feng, C | 1 |
| Fan, C | 1 |
| Yang, Y | 1 |
| Lu, H | 1 |
| Lu, Q | 1 |
| Zhu, F | 1 |
| Xiang, C | 1 |
| Zhang, Z | 1 |
| He, P | 1 |
| Zuo, J | 1 |
| Tang, W | 1 |
| Han, YB | 1 |
| Tian, M | 1 |
| Wang, XX | 1 |
| Fan, DH | 1 |
| Li, WZ | 1 |
| Wu, F | 1 |
| Liu, L | 1 |
| Liu, YM | 1 |
| Niu, L | 1 |
| Wang, LL | 1 |
| Bai, L | 1 |
| Fang, XY | 1 |
| Li, YC | 1 |
| Yi, LT | 1 |
| Wu, X | 1 |
| Li, X | 1 |
| Dang, Z | 1 |
| Jia, Y | 1 |
| Yao, J | 1 |
| Kong, W | 1 |
| Jiang, J | 1 |
| Li, YH | 1 |
| Xiao, HT | 1 |
| Hu, DD | 1 |
| Fatima, S | 1 |
| Lin, CY | 1 |
| Mu, HX | 1 |
| Lee, NP | 1 |
| Bian, ZX | 1 |
| Vuddanda, PR | 1 |
| Chakraborty, S | 1 |
| Singh, S | 1 |
| Linn, YC | 1 |
| Lu, J | 1 |
| Lim, LC | 1 |
| Sun, H | 1 |
| Sun, J | 1 |
| Zhou, Y | 1 |
| Ng, HS | 1 |
| Wu, YH | 1 |
| Jiang, GS | 1 |
| Zhagn, SZ | 1 |
| Bian, HZ | 1 |
| Zhu, SP | 1 |
| Zeng, X | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assess the Effects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus Among Individuals With High Cardiometabolic Risk[NCT05749874] | Phase 4 | 6,500 participants (Anticipated) | Interventional | 2023-04-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for berberine and Chronic Disease
| Article | Year |
|---|---|
Immunological axis of berberine in managing inflammation underlying chronic respiratory inflammatory diseases.
Topics: Anti-Inflammatory Agents; Berberine; Chronic Disease; Gene Expression Regulation; Humans; Inflammati | 2020 |
Berberine in the treatment of metabolism-related chronic diseases: A drug cloud (dCloud) effect to target multifactorial disorders.
Topics: Animals; Berberine; Chronic Disease; Drug Delivery Systems; Energy Metabolism; Humans; Metabolic Dis | 2020 |
Learning from berberine: Treating chronic diseases through multiple targets.
Topics: Berberine; China; Chronic Disease; Diabetes Mellitus, Type 2; Heart Diseases; Humans; Hyperlipidemia | 2015 |
Berberine: a potential phytochemical with multispectrum therapeutic activities.
Topics: Berberine; Biological Availability; Chronic Disease; Clinical Trials as Topic; Drug Delivery Systems | 2010 |
2 trials available for berberine and Chronic Disease
| Article | Year |
|---|---|
Berberine-induced haemolysis revisited: safety of Rhizoma coptidis and Cortex phellodendri in chronic haematological diseases.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Berberine; Bilirubin; Chronic Disease; Cohort | 2012 |
[The clinical study on the adjunctive effects of aqueous extract from coptis root for the treatment of chronic periodontitis].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Berberine; Chronic Disease; Coptis; Dental Scaling; | 2004 |
9 other studies available for berberine and Chronic Disease
| Article | Year |
|---|---|
Berberine improved experimental chronic colitis by regulating interferon-γ- and IL-17A-producing lamina propria CD4
Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Animals; Berberine; CD4-Positive T-Lymphocyte | 2019 |
Circadian pharmacological effects of berberine on chronic colitis in mice: Role of the clock component Rev-erbα.
Topics: Animals; Anti-Inflammatory Agents; Berberine; Bone Marrow Cells; Chronic Disease; Circadian Rhythm; | 2020 |
Mechanism of berberine in treating Helicobacter pylori induced chronic atrophic gastritis through IRF8-IFN-γ signaling axis suppressing.
Topics: Animals; Anti-Inflammatory Agents; Berberine; Cell Line; Cell Proliferation; Cell Survival; Chemokin | 2020 |
Intervention of oncostatin M-driven mucosal inflammation by berberine exerts therapeutic property in chronic ulcerative colitis.
Topics: Animals; Berberine; Chronic Disease; Colitis, Ulcerative; Humans; Inflammation; Intestinal Mucosa; M | 2020 |
Berberine ameliorates obesity-induced chronic inflammation through suppression of ER stress and promotion of macrophage M2 polarization at least partly via downregulating lncRNA Gomafu.
Topics: Animals; Anti-Inflammatory Agents; Berberine; Cell Differentiation; Chronic Disease; Cytokines; Dise | 2020 |
Berberine attenuates depressive-like behaviors by suppressing neuro-inflammation in stressed mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Berberine; Chronic Disease; | 2017 |
Berberine demonstrates anti-inflammatory properties in Helicobacter pylori-infected mice with chronic gastritis by attenuating the Th17 response triggered by the B cell-activating factor.
Topics: Animals; Anti-Inflammatory Agents; B-Cell Activating Factor; Berberine; Cells, Cultured; Chronic Dis | 2018 |
Berberine ameliorates chronic relapsing dextran sulfate sodium-induced colitis in C57BL/6 mice by suppressing Th17 responses.
Topics: Animals; Berberine; Cells, Cultured; Chronic Disease; Colitis; Colon; Dextran Sulfate; Disease Model | 2016 |
Relationship between the clinical effects of berberine on severe congestive heart failure and its concentration in plasma studied by HPLC.
Topics: Aged; Anticoagulants; Berberine; Blood Pressure; Chromatography, High Pressure Liquid; Chronic Disea | 1999 |